An interventional study of PET/CT in Staphylococcus Aureus Bacteremia, Staphylococcus Aureus Septicemia and Sepsis Bacterial, sponsored by University College, London. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-05-15.
Sponsored by University College, London · Not applicable, Interventional, and Diagnostic
Having bacteria in the blood can be very dangerous. This is called bacteraemia (or bacteremia) or bloodstream infection. It can lead to problems across the whole body, which is what happens in sepsis. Bacteria called Staphylococcus aureus (S. aureus) cause one kind of bacteraemia. Up to a third of people with this condition die within three months, even with antibiotics. One reason for such severe problems is that the bacteria can spread almost anywhere in the body, and hide in places where they are very hard to find. When people with S. aureus bacteraemia come into hospital and have had antibiotics, doctors sometimes cannot tell if they still have an infection source (called a 'focus') hiding in their body. The focus can be like an abscess and may need removing or the pus draining out. A focus might be obvious, if there is pain or swelling, or it might be hidden and deep. If these 'foci' can be found, then doctors can treat them and this helps to cure patients.
To improve survival for patients with these life-threatening infections, it is vital that doctors find the focus of S. aureus bacteraemia as quickly as possible. However, the research team do not know the best way to do this. Most patients with S. aureus bacteraemia have a chest X-ray and a scan of the heart valves. Patients may go to the scanning department lots of times while doctors try to work out where these foci are. This is uncomfortable and takes a lot of time. In about 1 in 5 cases the doctors still cannot find the focus. This is very worrying for patients, their relatives and doctors.
This study has been designed by researchers, doctors and patient advocates. It aims to work out if fewer patients may die when a specific type of scan called a 'PET/CT' is done quickly, because it finds more foci. To do this the team plan to do a clinical trial in patients with S. aureus bacteraemia. Half of the patients will receive the usual tests that patients currently get and the other half will receive an extra scan as soon as possible. The patients will be chosen randomly (like the flip of a coin) to go into one of the 2 groups. A year into the trial, an independent committee will check the results to make sure the extra scan is finding more foci. If this is the case, the trial will carry on. At the end of the study, we will share the results globally. The findings are expected to change the way this dangerous condition is managed, so patients do better.
Staphylococcus aureus (S. aureus) bacteraemia/bloodstream infection (SAB) is associated with deep foci in a high proportion of cases, through local or haematogenous spread or seeding. Detecting infectious foci in SAB is a prerequisite to source control, which is critical to improving outcomes. However, in up to 1 in 5 cases no focus can be found, and in others additional foci may be missed. When the foci are not found, this is associated with higher mortality.
Positron emission tomography/computed tomography (usually with 18-fluorodeoxyglucose (FDG), denoted PET/CT) is increasingly available worldwide. The role of PET/CT to rapidly detect deep infectious foci in SAB is becoming clearer with increasing use. The European Medicines Agency licensed FDG for use in PET/CT investigation of bacteraemia based on observational studies. Single-centre observational studies have found PET/CT detected infectious foci in the majority of cases of SAB. A prospective matched cohort study found a suggestion of improved survival with the use of PET/CT, though the rates of solid malignancies and nosocomial infection were higher in the control group. This is a multi-centre randomised controlled trial (RCT) of PET/CT in SAB.
The hypothesis is that PET/CT within 14 days of platform entry to SNAP enables the detection of new foci of infection leading to improved clinical outcomes.
The null hypothesis is that a composite of 90-day all-cause mortality or microbiological relapse or microbiological treatment failure will not be changed by early PET/CT in SAB.
Primary outcome:
A composite of 90-day all-cause mortality or microbiological relapse or microbiological treatment failure 90 days after platform entry.
Secondary outcomes:
The detection of new foci between 0 and 90 days after platform entry. The presence of new foci will be determined by the site investigator and can incorporate clinical, radiological, microbiological and pathological findings.
The presence of new foci will be determined by the site investigator and can incorporate clinical, radiological, microbiological and pathological findings.
All cause mortality at 90 days after platform entry Duration of survival censored at 90 days after platform entry. Length of stay of acute index inpatient hospitalisation for those surviving until hospital discharge (excluding or including HITH/COPAT/OPAT/rehab) truncated at 90 days after platform entry Time to being discharged alive from the total index hospitalisation (excluding or including HITH/COPAT/OPAT/rehab) truncated at 90 days after platform entry.
Microbiological treatment failure defined as positive sterile site culture for S. aureus between 14 and 90 days after platform entry.
Total radiation exposure Patient Eligibility Criteria Inclusion criteria: Adult (≥18 years of age) and consented to the SNAP platform. Agrees to PET/CT.
Exclusion criteria:
Contraindication to PET/CT (including pregnancy/breast-feeding) PET/CT in the last 7 days or already planned to occur in the next 7 days.
2,416 studies on the registry are indexed under Sepsis; 541 are open to participants now.
This study's planned enrollment of 820 is above the median of 102 across 1,165 interventional studies indexed under Sepsis.
Browse Sepsis studies →University College, London is the lead sponsor of 651 studies on the registry; 149 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 2 (33%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Enhanced imaging with PET/CT
Diagnostic Test: PET/CT
Standard of Care Imaging
Enhanced imaging with PET/CT
Also known as: PET-CT
Mortality
All cause mortality- Number of participants who are no longer alive at day 90
Time frame: 90 days
Total antibiotic days
Total number of days of antibiotic and type (IV or oral delivery) per participant measured at day 90
Time frame: 90 days
Source control
Control of infection sites through surgery, drainage and other procedures- Number of participants who receive these procedures and number of participants in whom these procedures are not completed but infectious foci remain
Time frame: Time to hospital total discharge [up to 90 days from platform entry]
Number of participants with a change in the planned management strategy
Number of participants with a change in the planned management strategy by date of total hospital discharge (including OPAT)
Time frame: Time to hospital total discharge [up to 90 days from platform entry]
Length of Stay
Length of stay of acute index inpatient hospitalisation for participants surviving until hospital discharge
Time frame: 90 days
Microbiological failure and relapse
Microbiological treatment failure and relapse defined as positive sterile site culture for S. aureus from a participant
Time frame: From 14 to 90 days
Adverse events including total radiation exposure
Total radiation exposure to the participant and serious adverse events
Time frame: 90 days
Diagnosis of new infectious foci
Detection of Deep Foci of Infection in the participant (location). The presence of deep foci will be determined by the site investigator and can incorporate clinical, radiological, microbiological and pathological findings.
Time frame: Up to 90 days after platform entry
Composite of 90-day all-cause mortality or microbiological relapse or microbiological treatment failure.
Number of participants with a composite of 90-day all-cause mortality or microbiological relapse or microbiological treatment failure. Microbiological relapse is defined as a positive blood culture for S. aureus at least 72 hours after a preceding negative culture. Microbiological treatment failure is defined as a positive sterile-site culture for S. aureus of the same antibiotic resistance as the index isolate at least 21 days after platform entry.
Time frame: Up to 90 days after platform entry
No study locations are listed for this record.
Plan to share: Yes — This will be determined with the protocol. It is will be open but would need to protect patient identifiable data.
Supporting information: Study protocol, Statistical analysis plan
Time frame: To be determined
Access criteria: Open access Study Protocol
No publications or documents are linked to this record.
Start is estimated for Sep 2023; primary completion for Jan 2026, 28 months later.
Of 301 non-industry interventional studies with no phase under Sepsis, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 42. This study's planned 28 months is above that.
Counting every sponsor, half of 324 studies reached it within 22 months; a quarter within 12 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in May 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.